트라스투주맙 바이오시밀러 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global trastuzumab biosimilars market size is expected to reach USD 73.85 Billion in 2034 from USD 7.45 Billion in 2025, growing at a CAGR of 29.03 during 2026-2034.This market is experiencing robust growth due to increasing demand for affordable treatment options for HER2-positive cancers. Trastuzumab biosimilars provide comparable efficacy and safety to reference biologic therapies while offering cost advantages for healthcare systems and patients. Rising cancer prevalence, growing awareness of biosimilar therapies, and efforts to reduce healthcare costs are driving market expansion. Governments and healthcare providers are increasingly supporting biosimilar adoption to improve treatment accessibility.

The oncology sector remains a major growth driver as healthcare systems seek cost-effective therapeutic alternatives. Expanding regulatory approvals and increasing physician confidence in biosimilars are supporting broader market penetration. Pharmaceutical companies are investing in biosimilar development to meet growing demand for cancer therapies. Improved access to biologic treatments in emerging economies is also contributing to market growth and patient adoption.

Future prospects remain highly favorable as healthcare systems continue prioritizing affordable cancer care solutions. Increased competition among biosimilar manufacturers is expected to improve accessibility and pricing. Advances in biotechnology and expanding biosimilar pipelines will create additional opportunities. As cancer incidence continues to rise globally, trastuzumab biosimilars will play an important role in expanding access to effective oncology treatments.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

• Ogivri
• Herzuma
• Ontruzant
• Trazimera
• Other Products

By Indication

• Adjuvant Breast Cancer
• Metastatic Breast Cancer
• Metastatic Gastric Cancer
• Other Indications

By Distribution Channel

• Hospital Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• Pfizer Inc., Amgen Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Biocon Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Shanghai Henlius Biotech Inc., Alvotech Holdings S.A., Dr. Reddy's Laboratories Limited, Zydus Lifesciences Limited, Intas Pharmaceuticals Limited, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TRASTUZUMAB BIOSIMILARS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Ogivri Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Herzuma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Ontruzant Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Trazimera Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TRASTUZUMAB BIOSIMILARS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Adjuvant Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Metastatic Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Metastatic Gastric Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TRASTUZUMAB BIOSIMILARS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TRASTUZUMAB BIOSIMILARS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TRASTUZUMAB BIOSIMILARS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Amgen Inc
  • 9.2.3 Samsung Bioepis Co. Ltd
  • 9.2.4 Celltrion Inc
  • 9.2.5 Biocon Limited
  • 9.2.6 Teva Pharmaceutical Industries Ltd
  • 9.2.7 Mylan N.V
  • 9.2.8 Shanghai Henlius Biotech Inc
  • 9.2.9 Alvotech Holdings S.A
  • 9.2.10 Dr. Reddy's Laboratories Limited
  • 9.2.11 Zydus Lifesciences Limited
  • 9.2.12 Intas Pharmaceuticals Limited
  • 9.2.13 Fujifilm Kyowa Kirin Biologics Co. Ltd
  • 9.2.14 Innovent Biologics Inc
  • 9.2.15 STADA Arzneimittel AG